Intellia Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- John Leonard
- Full Time Employees
- 377
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 40 Erie Street Cambridge MA United States of America 02139
- IPO Date
- May 6, 2016
- CIK
- 0001652130
- Website
- intelliatx.com
- Similar Companies
- Business
- Intellia Therapeutics, Inc. Intellia Therapeutics, Inc. (NTLA) is a clinical-stage biotechnology company focused on developing potentially curative CRISPR/Cas9-based gene editing therapeutics for severe genetic diseases, cancers, and autoimmune disorders; its core pipeline includes nexiguran ziclumeran (nex-z, formerly NTLA-2001) in Phase 3 trials for transthyretin (ATTR) amyloidosis with polyneuropathy (ATTRv-PN) and cardiomyopathy (ATTR-CM), lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) in Phase 3 HAELO trial for hereditary angioedema (HAE) with topline data expected mid-2026, NTLA-3001 for ATTR amyloidosis, NTLA-4001 for T-cell malignancies, and research programs in hemophilia B (partnered with Regeneron Pharmaceuticals, Inc.), hematological disorders such as sickle cell disease and beta-thalassemia, as well as immuno-oncology and autoimmune disease targets. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company leverages a modular gene editing platform for in vivo and ex vivo therapies, supported by collaborations including Regeneron for ATTR amyloidosis co-development and cost reimbursements. Recent developments encompass completion of enrollment in the Phase 3 HAELO trial for lonvo-z in September 2025 ahead of schedule, presentation of positive longer-term Phase 1/2 data for nex-z and lonvo-z at ACAAI 2025 and other conferences, advancement in the Phase 3 MAGNITUDE trial for ATTR-CM, a strategic reorganization in early 2025 to prioritize late-stage programs, inducement equity grants under the 2024 Inducement Plan to support expansion, and a cash position of approximately $670 million as of Q3 2025 expected to fund operations into mid-2027 including potential U.S. commercial launch of lonvo-z in H1 2027.
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%
Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?
Dow Extends Record Run as Fed Decision Looms
This Stock Is Up 58% This Year. Is It too Late to Buy?
NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up
Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?
Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound?
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026
Intellia Therapeutics - Steady Progress, Historic Commercial Approval In Sight
ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now?
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?
Intellia Therapeutics, Inc. (NTLA) Presents at Bank of America Global Healthcare Conference 2026 Transcript